Clinical Trial

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Study acronym: PROACT

Recruiting Phase 2

Summary

Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-07-28; most recent amendment 2026-02-13.

Trial Details

NCT Number	NCT07101939
Lead Sponsor	Actimed Therapeutics Ltd Collaborators: SCIRENT Clinical Research and Science d.o.o.
Conditions	Obesity, Muscle Loss
Enrollment	120 participants
Start Date	2025-06-23
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-02-17